JTO Clin Res Rep 2024 Feb
The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC.
Related Questions
What is your preference?
New comment by Medical Oncologist at Hollywood Private Hospital ( July 5, 2025)
Thank you. If there are no trials available but there is access to gilteritinib, would that be a reasonable choice to consider?